

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Richard Durley

Serial No. 10/808,146

Filed: March 24, 2004

For SUBSTITUTED PYRIMIDINONES



)
) Attorney Docket No. 01640/1
)

) Group Art Unit: 1614
)

) Examiner: Unknown
)

July 14, 2004

Commissioner of Patents
PO Box 1450
Alexandria, VA 22313

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Julie M. Lappin".

Julie M. Lappin,
Reg. No. 46,612

Attorney for Applicants
(314) 274-2009 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006



IFW

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

Serial No. 10/808,146
Filing Date: 3/24/04
Examiner: Unknown
Group Art Unit: 1614
Docket No. 01640/1

Date of Deposit: July 14, 2004


I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

13 IDS References
IDS Form 1449
IDS Statement
Post Card

Michelle Becker

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)



Sheet 1 of 1

PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01640/1 US	APPLICATION NO.: 10/808,146
	INVENTOR: Richard Durley	
	Filed: 3/24/04	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	1	Trandism Cell Biology; 7; 353-361; 1997
	2	Mol. Cell Biology; 19; 21-30; 1999
	3	Embo J.; 20; 466-479; 2001
	4	Paul et al; Cell Signal; 9; 403-410; 1997
	5	Lee et al; Nature; 372; 376; 1994
	6	J. Biol. Chem; 274; 6272; 1999
	7	JPET; 293; 281; 2000
	8	Boehm et al; Exp Opin Ther Patents; 10; 25; 2000
	9	Rev. Infect. Disease; 6; 51; 1984
	10	Lymphokien Cytokine Res.; 11; 253-256; 1992
	11	Clin. Exp. Immunol.; 989; 244-250; 1992
	12	Perretti, M et al; Br. J. Pharmacol; 110; 868-874; 1993
	13	J. M. Stuart; Collagen Autoimmune Arthritis; Annual Rev. Immunol; 2; 199; 1984

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	